Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iCeutica has announced that its wholly owned subsidiary has been awarded a key patent for its SoluMatrix Fine Particle Technology platform by the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The patent, No. 8,808,751, covers the company’s dry milling method for producing submicron-sized particles that are 10 to 200 times smaller than conventional drug particles.
"This patent further strengthens our intellectual property around the SoluMatrix technology, which serves as the foundation of our business model of creating enhanced branded medications with improved pharmacokinetics and therapeutic effect," said Matt Callahan, CEO of iCeutica.
"SoluMatrix technology has already been incorporated into two FDA approved drugs in three indications and has fueled 15 of iCeutica’s additional pipeline candidate programs. This patent grant by the USPTO is an important milestone in our goal of protecting the commercial potential of products utilizing our proprietary technology platform."
The SoluMatrix Fine Particle Technology platform can improve novel as well as marketed drugs in several ways: by increasing oral bioavailability, reducing or eliminating food effects, achieving efficacy at lower doses, avoiding excessive peak plasma levels, improving time to onset of action and reducing pharmacokinetic variability.
Utilizing this technology, iCeutica is currently developing its own pipeline of products, pursuing a broad range of indications including pain and inflammation, oncology (with a lead program in prostate cancer) and respiratory diseases.
"iCeutica partners with other pharmaceutical companies whose products may benefit from improved solubility," said Bill Bosch, CSO of iCeutica.
"Products already approved by the FDA that utilize the SoluMatrix Technology under a license from iCeutica are Iroko Pharmaceutical’s Zorvolex (diclofenac capsules), which has received approvals for two indications, including management of mild to moderate acute pain and management of osteoarthritis pain in adults and Tivorbex (indomethacin capsules) for treatment of mild to moderate acute pain in adults."